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Abstract: Second generation antipsychotics are associated with the risk of metabolic disorders 
such as diabetes mellitus and hyperlipidemia. Remnant-like lipoprotein particles cholesterol 
(RLP-C) are a known risk factor for cardiovascular events. The present study was performed to 
determine possible differences in fasting blood RLP-C levels between schizophrenic patients 
treated with risperidone as compared to olanzapine. Patients on olanzapine had signiﬁ  cantly 
higher RLP-C levels than those on risperidone (p  0.01). In olanzapine-treated patients there 
was no abnormality in fasting blood glucose levels, but fasting insulin levels and homeostasis 
model assessment of insulin resistance (HOMA-IR) were elevated. RLP-C levels were signiﬁ  -
cantly correlated with plasma triglyceride concentrations in both the olanzapine- (p  0.01) and 
risperidone-treated patients (p  0.01). The regression line slope was greater for the olanzapine 
group, suggesting a greater inﬂ  uence of olanzapine on RLP-C. There was a signiﬁ  cant correlation 
between RLP-C and HOMA-IR in the risperidone group (p  0.01) but not in the olanzapine 
group (p = 0.80). These results suggest that blood glucose monitoring may not be sufﬁ  cient to 
detect metabolic disorder and that measurement of RLP-C might be helpful for the screening 
for metabolic disorders associated with olanzapine therapy.
Keywords: remnant-like lipoprotein particles cholesterol (RLP-C), schizophrenia, insulin 
resistance, risperidone, olanzapine
Introduction
The adverse reactions referred to as the metabolic syndrome (including diabetes 
mellitus and hyperlipidemia) associated with second generation antipsychotics have 
been gaining considerable attention. Approximately 40% of treated patients have 
the metabolic syndrome according to Clinical Antipsychotic Trials of Intervention 
Effectiveness (CATIE), a large-scale clinical study conducted to assess the useful-
ness of antipsychotic drugs (McEvoy et al 2005). The molecular mechanism that 
underlies the metabolic syndrome is insulin resistance and it has become common 
practice to monitor body weight and blood glucose levels in patients receiving 
second generation antipsychotics. However, the frequency of metabolic syndrome 
continues to increase and monitoring with more sensitive markers than blood sugar 
are required. Disorders of neutral fat metabolism are readily detectable and more 
sensitive than those of carbohydrate metabolism in patients with insulin resistance 
(Tanaka 2004). Of the neutral fats, the one which directly constitutes a risk for 
cardiovascular events is remnant-like lipoprotein particles cholesterol (RLP-C) 
(Devaraj et al 1998).
The present study was designed to determine whether there was any difference 
in blood RLP-C levels between treatment with risperidone and with olanzapine in Neuropsychiatric Disease and Treatment 2008:4(2) 482
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patients in the maintenance stage of schizophrenia who had 
no indications of diabetes mellitus.
Subjects and methods
Outpatients with schizophrenia who initiated or were 
switched to either risperidone or olanzapine for at least 
40 weeks were included in the study. Concomitant ben-
zodiazepines were allowed. Inclusion criteria included a 
body mass index (BMI) of less than 30 and a fasting blood 
sugar level of less than 126 mg/dL prior to initiation of 
risperidone or olanzapine therapy. Patients whose dietary 
intake was unstable due to instability of disease condition 
and patients receiving treatment for diabetes mellitus or 
hyperlipidemia were excluded from the study. All patients 
fulﬁ  lling these criteria in our department from July 2002 
to December 2004 and who gave their written informed 
consent were enrolled in the study.
Body weight measurement and collection of fasting 
blood samples were performed on any day after 40 weeks of 
treatment with oral risperidone or olanzapine. The follow-
ing blood biochemical parameters were determined: RLP-C, 
total cholesterol, high-density lipoprotein (HDL) cholesterol, 
triglycerides, glucose, and insulin. RLP-C was determined 
in terms of cholesterol present in the remnant-like particles 
(RLP) fraction. RLP was measured as an unbound fraction 
in serum to anti-human apo A-I and anti-human apo B-100 
monoclonal antibody immunoafﬁ  nity mixed gel (Nakajima 
et al 1996).
Differences between the olanzapine and risperidone 
groups were evaluated using unpaired, two-sided t-test, and 
any differences were considered statistically signiﬁ  cant at 
p  0.05. For each treatment group, the data were analyzed 
to see whether there is any signiﬁ  cant correlation between 
RLP-C and triglycerides and between RLP-C and the homeo-
stasis model assessment of insulin resistance (HOMA-IR).
Results
Age, study treatment duration and body 
weight changes
A total of 14 patients (8 males and 6 females) received ris-
peridone and 14 patients (9 males and 5 females) received 
olanzapine. Patient demographic characteristics are shown 
in Table 1. No signiﬁ  cant differences were noted between the 
two groups in terms of age, pre-treatment (baseline) body 
weight or treatment duration. The baseline blood sugar levels 
were signiﬁ  cantly higher in the risperidone group.
Following treatment, small body weight changes were noted 
in both treatment groups compared to baseline values. Mean 
weight gain was 0.76 kg and 1.51 kg for the risperidone group 
and the olanzapine group, respectively. However, the intergroup 
difference in weight gain was not signiﬁ  cant (Table 1).
Metabolic indicators
Post-treatment blood glucose levels were not signiﬁ  cantly 
different between the two treatment groups. RLP-C values 
and serum triglyceride levels, however, were signiﬁ  cantly 
higher in the olanzapine group (Table 2). There were no sig-
niﬁ  cant differences for total cholesterol and HDL cholesterol 
between the two treatment groups (Table 2). The olanzapine 
group showed signiﬁ  cantly higher fasting blood insulin lev-
els than the risperidone group and the HOMA-IR was also 
signiﬁ  cantly higher for this group (Table 2).
Relationship between RLP-C 
and triglycerides
There was a signiﬁ  cant correlation between the RLP-C levels 
and triglyceride levels in both the risperidone and olanzapine 
groups (Figure 1; r = 0.8290, p  0.001 for the risperidone 
group; r = 0.8552, p  0.001 for the olanzapine group). The 
slope of the regression line for the olanzapine group was 
Table 1 Demographic characteristics
  Risperidone-treated   Olanzapine-treated  p value
 patients  patients
Age (years)  57.5 ± 7.2  51.3 ± 15.6  0.19
Sex 6f/8m  5f/9m  -
Baseline body weight (kg)  59.7 ± 8.5  64.6 ± 11.9  0.23
Baseline glucose (mg/dL)  116.2 ± 9.0  101.7 ± 6.8  0.01
Treatment duration (weeks)  135.2 ± 46.8  101.1 ± 43.8  0.057
Mean antipsychotic dose (mg/day)  4.7 ± 2.0  13.2 ± 4.6  -
Antipsychotic dose range  2–8 mg  5–20 mg  -
Body weight change during treatment (kg)  0.76 ± 1.30  1.51 ± 1.89  0.23
Notes: Values are given as mean ± SEM. Signiﬁ  cant p values are indicated in bold text.Neuropsychiatric Disease and Treatment 4008:4(2) 483
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about two-fold greater than that of the regression line for 
the risperidone group.
Relationship between RLP-C 
and HOMA-IR
There was also a signiﬁ  cant correlation of RLP-C with 
HOMA-IR in the risperidone group (Figure 2; r = 0.7323, 
p = 0.003); whereas in the olanzapine group, there was no 
such relationship (Figure 2; r = 0.0739, p = 0.80).
Discussion
Blood RLP-C levels were measured in patients with 
stable chronic phase schizophrenia receiving risperidone 
or olanzapine therapy in the usual outpatient setting of a 
clinical practice. The observation period was approximately 
two years (mean 135.2 weeks for the risperidone group and 
101.1 weeks for the olanzapine group). Both therapy groups 
showed only minimal body weight changes during this period. 
The baseline (pre-treatment) blood sugar levels were signiﬁ  -
cantly higher in the risperidone group. This difference may 
be due to the fact that olanzapine, which is contraindicated 
in diabetic patients in Japan, is unlikely to be prescribed to 
patients with blood glucose levels at the upper level of the 
normal range. Since RLP-C levels are not routinely mea-
sured in clinical practice in Japan, baseline values (before 
antipsychotic therapy) were not available. We have assumed 
Table 2 Post-treatment carbohydrate and lipid metabolism markers
 Risperidone-treated  Olanzapine-treated  p  value
 patients  patients
Glucose (mg/dL)  119.1 ± 13.3  111.9 ± 16.6  0.22
Insulin(µIU/L) 5.5  ± 3.1  9.2 ± 4.2  0.015
HOMA-IR 1.65  ± 0.95  2.50 ± 1.13  0.042
RLP cholesterol (mg/dL)  4.17 ± 1.77  9.80 ± 5.32  0.01
Triglycerides (mg/dL)  105.6 ± 62.3  185.9 ± 87.9  0.01
Total cholesterol (mg/dL)  196.1 ± 27.9  189.1 ± 32.5  0.55
HDL cholesterol (mg/dL)  61.7 ± 11.9  57.4 ± 16.8  0.44
Notes: Values are given as mean ± SEM. Signiﬁ  cant p values are indicated in bold text.
Abbreviations: HOMA-IR, homeostasis model assessment of insulin resistance; RLP, remnant-like lipoprotein particles; HDL, high density lipoprotein.
Figure 1 Relationship between levels of RLP-C and triglycerides.
Risperidone r = 0.829042 p = 0.0002.
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that the two groups would have had comparable baseline 
levels RLP-C levels. It is however, possible that since patients 
treated with risperidone had higher baseline glucose levels, 
they may also have had higher RLP-C levels. Higher glucose 
levels and higher RLP-C levels have been shown tend to go 
together in diabetic patients (Tanaka 2004). In this case the 
difference seen in RLP-C levels following therapy would be 
even more meaningful.
Following treatment, blood glucose, total cholesterol, and 
HDL cholesterol were within normal limits in both groups 
and showed no signiﬁ  cant intergroup difference. Blood 
RLP-C levels were within the normal limits in the risperidone 
group but in the olanzapine group they were signiﬁ  cantly 
higher. The olanzapine group showed normal blood glucose 
levels with elevated fasting blood insulin values. The insulin 
resistance indicator HOMA-IR for this group (mean: 2.50) 
exceeded the reference value of 2 and differed signiﬁ  cantly 
from the value found for the risperidone group (mean: 1.65) 
which was within normal limits.
Results of large-scale clinical trials (CATIE) have indi-
cated the therapeutic usefulness of risperidone and olanzap-
ine, which were randomized to patients who had dropped out 
of previous drug therapies. The dropout rates with risperidone 
and olanzapine were lower than with quetiapine and zipra-
sidone (Stroup et al 2005). However, when viewed in terms 
of metabolism and triglycerides in particular, a signiﬁ  cant 
elevation in triglycerides was observed in patients receiving 
olanzapine, whereas this metabolic indicator was decreased 
in patients receiving risperidone even after adjustment for the 
duration of exposure to the drugs (Akuzawa et al 1995).
In the present study, the olanzapine group also exhibited 
signiﬁ  cantly higher serum triglyceride levels than the ris-
peridone group. RLP-C is an intermediate metabolite of tri-
glycerides. Under normal conditions, RLP-C is metabolized 
very rapidly. Lipoprotein lipase activity, hepatic triglylipase 
activity, and remnant receptor activity are involved in the 
catabolism of RLP-C. All these enzyme and receptor activi-
ties are diminished in the presence of insulin resistance. The 
elevated RLP-C seen in the olanzapine group in the present 
study is probably the consequence of the insulin resistance 
as indicated by the rise in HOMA-IR.
RLP-C is readily taken up by macrophages in the arte-
rial wall and facilitates foamy changes of the macrophages, 
thereby leading to formation of atherosclerotic plaques. 
RLP-C has been demonstrated to promote arteriosclerosis via 
formation of atherosclerotic plaques due to enhanced uptake 
by macrophages, increased platelet aggregation, enhanced 
PAI-1 activity, impaired vascular endothelial cell function, 
and enhanced monocyte adhesion to the endothelium (Tanaka 
et al 2004). RLP-C may be elevated in patients with coronary 
Figure 2 Relationship between levels of RLP-C and HOMA-IR.
Risperidone r = 0.732270 p = 0.0029.
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diseases, has been described to correlate with pathological 
changes in coronary arteries, and is increasingly seen as a risk 
factor for cardiovascular events (Takeichi et al 1999).
Although insulin resistance is presumed to be the cause 
of the high RLP-C levels in patients receiving olanzapine in 
this study, neither treatment group showed appreciable body 
weight changes (7% in both groups). The insulin resistance 
observed in the olanzapine group might thus be attributable 
to a difference between olanzapine and risperidone, namely, 
a possible direct effect of olanzapine to induce insulin resis-
tance, rather an effect associated with body weight gain. 
The mechanism whereby olanzapine exerts a direct effect 
on metabolism remains unclear. Nonetheless, several previ-
ous studies have shown olanzapine to be directly linked to 
insulin resistance. Based on assessment of HOMA-IR and 
an oral glucose tolerance test, clozapine and olanzapine, but 
not risperidone and other atypical antipsychotic drugs, have 
been shown to cause insulin resistance in a patient popula-
tion adjusted for BMI to eliminate the effects of weight gain 
(Newcomer et al 2002). A study in non-obese, non-diabetic 
patients showed that patients receiving clozapine or olan-
zapine had high fasting blood insulin levels and increased 
HOMA-IR and leptin values, again indicating insulin 
resistance (Henderson et al 2005). They also showed that 
the insulin sensitivity index calculated by minimal model 
analysis, based on an intravenous glucose tolerance test 
(IVGTT), was signiﬁ  cantly lower for clozapine and olanzap-
ine, compared to risperidone (Henderson et al 2005).
The relationship of RLP-C with triglycerides differed 
slightly between the risperidone group and the olanzapine 
group. In both groups, RLP-C was signiﬁ  cantly correlated 
with triglycerides (Figure 1). The regression equation for 
the risperidone group in this study closely resembles that 
of correlation between RLP-C and triglycerides for healthy 
Japanese adult volunteers (Akuzawa et al 1995) which was 
considered to represent a physiological correlation. However, 
the slope of the regression line for the olanzapine group was 
about two-fold greater than that of the risperidone group. 
This suggests that patients with increased triglyceride levels 
might show a further elevation in RLP-C during olanzapine 
therapy suggesting that RLP-C metabolism maybe slowed 
in the olanzapine-treated patients. It would be reasonable to 
assume that the difference concerning the correlation between 
the intermediate of neutral fat RLP-C and triglycerides indi-
cates a qualitative change in triglyceride-rich lipoprotein. 
RLP-C are heterogenous in their physical and biochemical 
properties because they are assayed by immunoseparation. 
In subjects with increased serum triglycerides, the ratio of 
RLP-C to remnant-like particles triglyceride (RLP-TG) 
correlates with the particle size, an important factor in the 
atherogenic effect, while the ratio of RLP-C to triglycerides 
does not correlate with particle size (Okazaki et al 2002). 
The increase in RLP-C has been shown to be inversely pro-
portional to LDL cholesterol particle size, so that elevation 
in RLP-C leads to an increase in small dense LDL which 
promotes progression of atherosclerosis (Takayanagi et al 
2004). Enhanced RLP-C is related to an increase in athero-
genic smaller-sized lipoprotein (Takayanagi et al 2004). The 
difference in pattern of correlation between RLP-C and tri-
glycerides (the slope of the regression line) observed between 
the olanzapine group and the risperidone group suggests 
that the particle size of lipoproteins may differ between the 
two groups. With the aim of estimating the atherogenicity it 
would be of interest, in the future, to evaluate triglycerides 
in the context of the RLP-C lipoprotein, just as cholesterol is 
evaluated in terms of the LDL-C and HDL-C lipoproteins.
The present data obtained on the relationship between 
RLP-C and HOMA-IR show completely different features 
between for the two therapy groups with a signiﬁ  cant cor-
relation of RLP-C with HOMA-IR only in the risperidone 
group (Figure 2). A signiﬁ  cant positive correlation between 
HOMA-IR and RLP-C has been reported in the general 
Japanese population (Ohnishi et al 2002). In contrast, in 
patients receiving olanzapine, RLP-C did not correlate with 
HOMA-IR (Figure 2). The olanzapine group displayed blood 
glucose levels within the normal limits but elevated RLP-C 
and insulin levels and no correlation of RLP-C to HOMA-
IR. These results suggest that, in the patients with chronic 
schizophrenia undergoing long-term olanzapine therapy, 
RLP-C may be in a state where it can no longer be controlled 
with insulin.
The weaknesses of the present study are principally its 
relatively small size and the fact that the patients were not 
randomized to one treatment or another. A number of fac-
tors can affect development of diabetes such as race, family 
history of diabetes, life-style, etc. Subjects from the two 
groups could not therefore be matched precisely. In addition 
all the subjects were of Japanese descent and it remains to be 
shown to what extent these results can be extended to other 
races. A larger randomized controlled trial is necessary to 
corroborate these data.
Conclusion
Patients with chronic schizophrenia showing stable blood glu-
cose levels are generally considered not to have any metabolic 
disorder. In patients receiving olanzapine, however, RLP-C, Neuropsychiatric Disease and Treatment 2008:4(2) 486
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an important risk factor for development of cardiovascular 
events, may be elevated even though their blood glucose 
levels are within the normal limits. Patients treated with 
risperidone showed relationships between RLP-C and tri-
glycerides and between RLP-C and HOMA-IR which were 
comparable with those seen in the general population, 
whereas patients taking olanzapine appeared to be in a state 
where RLP-C might not be controlled with insulin.
For insulin resistance, RLP-C is a more sensitive marker 
than blood glucose. Early detection of insulin resistance 
cannot be achieved by blood sugar monitoring alone. It is 
proposed that in patients taking olanzapine it may be help-
ful to monitor for metabolic disorders by measuring plasma 
RLP-C to detect insulin resistance even if the blood glucose 
level is normal.
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